An adaptive seamless phase II/III design for oncology trials with subpopulation selection using correlated survival endpoints†
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Although the statistical methods enabling efficient adaptive seamless designs are increasingly well established, it is important to continue to use the endpoints and specifications that best suit the therapy area and stage of development concerned when conducting such a trial. Approaches exist that allow adaptive designs to continue seamlessly either in a subpopulation of patients or in the whole population on the basis of data obtained from the first stage of a phase II/III design: our proposed design adds extra flexibility by also allowing the trial to continue in all patients but with both the subgroup and the full population as co‐primary populations. Further, methodology is presented which controls the Type‐I error rate at less than 2.5% when the phase II and III endpoints are different but correlated time‐to‐event endpoints. The operating characteristics of the design are described along with a discussion of the practical aspects in an oncology setting. Copyright © 2010 John Wiley & Sons, Ltd.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534 · cited 1×
“We have already commented that PFS (the minimum of time to death, time to the growth of existing lesions by a pre-specified amount or time to the occurrence of new lesions [15]) is not yet an acceptable endpoint for confirmatory phase III trials in all cancer types and so the use of a more traditional endpoint may be…”
Background
Cited by
Thuss-Patience, P. C., Shah, M. A., Ohtsu, A., Van Cutsem, E., Ajani, J. A., Castro, H., Mansoor, W., Chung, H. C., Bodoky, G., Shitara, K., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30111-0 · Cited by 547
Adaptive Designs for Clinical Trials
Bhatt, D. L., & Mehta, C. (2016) · New England Journal of Medicine · doi:10.1056/nejmra1510061 · Cited by 499
Dimairo, M., Pallmann, P., Wason, J., Todd, S., Jaki, T., Julious, S. A., Mander, A. P., Weir, C. J., Koenig, F., Walton, M. K., et al. (2020) · Trials · doi:10.1186/s13063-020-04334-x · Cited by 58
General guidance on exploratory and confirmatory subgroup analysis in late-stage clinical trials
Dmitrienko, A., Muysers, C., Fritsch, A., & Lipkovich, I. (2016) · Journal of Biopharmaceutical Statistics · doi:10.1080/10543406.2015.1092033 · Cited by 51
“Different types of adaptive population selection designs were examined in Brannath et al. (2009), Jenkins et al. (2011), Friede et al. (2012), and Stallard et al. (2014).”
Background
Metadata
- Authors
- Jenkins, M., Stone, A., & Jennison, C.
- Venue
- Pharmaceutical Statistics
- Publisher
- Wiley
- Published
- 2010-12-08
- Volume
- 10
- Issue
- 4
- Pages
- 347-356
- ISSN
- 1539-1604 (ISSN-L)
- 1539-1612
- OpenAlex
- W2127182852
- Cited by
- 213
- References
- 1
- FWCI
- 4.31
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: An adaptive seamless phase II/III design for oncology trials with subpopulation selection using correlated survival endpoints†. https://app.cochat.ai/papers/10.1002/pst.472
- The paper
- Jenkins, M., Stone, A., & Jennison, C. (2011). An adaptive seamless phase II/III design for oncology trials with subpopulation selection using correlated survival endpoints†. Pharmaceutical Statistics. https://doi.org/10.1002/pst.472
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.